Compare AbCellera Biologics Inc (ABCL) vs Deckers Outdoor Corp (DECK) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
AbCellera Biologics Inc vs Deckers Outdoor Corp — how do they compare? AbCellera Biologics Inc trades at $7.18 (market cap $2.35B), while Deckers Outdoor Corp trades at $101.22 (market cap $14.73B). The key difference: Deckers Outdoor Corp is far larger — about 6.3× AbCellera Biologics Inc's market cap, and AbCellera Biologics Inc is trading nearer its 52-week high, Deckers Outdoor Corp nearer its low. Which is the better fit depends on your goals.
| ABCL | DECK | |
|---|---|---|
Market Cap | $2.35B | $14.73B |
Sector | Health | Consumer Cyclical |
52-Week High | $8.12 | $123.91 |
52-Week Low | $2.78 | $79.54 |
Enterprise Value | $1.99B | $13.20B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AbCellera Biologics (ABCL) trades at $7.69, down 5.18% today, with a bullish technical signal from moving averages but overbought RSI readings. The company reported a net loss of -$146.41M in 2025, with negative margins, though revenue grew to $75.13M. Recent news highlights a major collaboration with Jazz Pharmaceuticals worth up to $876M, potentially boosting future revenue streams. Analyst consensus is strongly bullish with a $9.67 price target, indicating 25.7% upside.
The outlook hinges on execution of new partnerships and pipeline progress, particularly ABCL635 Phase 2 data expected in Q3 2026. Key risks include persistent cash burn, high valuation multiples despite losses, and biotech sector volatility. Investors should weigh the strong analyst support against fundamental challenges and the stock's current technical overbought condition.
Deckers Outdoor Corp (DECK) trades at $106.08, up 1.33% today, with a bullish technical signal from moving averages and strong fundamental performance. Revenue grew to $4.99B in 2025, with net income reaching $966M and a robust ROE of 40.86%. Recent quarters show consistent earnings beats, and analyst consensus targets $121.50. The stock benefits from international expansion of UGG and HOKA brands, as highlighted by Zacks Investment Research on 2026-07-01.
The outlook for DECK is positive, supported by earnings momentum and global growth initiatives, but risks include competitive pressures and market volatility. With a P/E of 15.05, the stock appears reasonably valued, offering potential upside to the consensus target. Investors should weigh strong profitability against sector headwinds.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About AbCellera Biologics Inc
AbCellera Biologics Inc is a biotechnology company. It develops antibodies to treat infectious diseases and various other types of diseases. The company's AI-powered technology sources, searches, decodes and analyzes antibody responses to engineer new antibody drug candidates for its partners.
Read more on ABCL →About Deckers Outdoor Corp
Deckers Outdoor Corp designs and sells casual and performance footwear, apparel, and accessories. Primary brands include UGG, Teva, and Sanuk. The company distributes Most of its products through its wholesale business, but it also has a substantial direct-to-consumer business with its company-owned retail stores and websites. Most sales are in the United States, although the company also has retail stores and distributors throughout Europe, Asia, Canada, and Latin America. Deckers sources its products from independent manufacturers primarily in Asia.
Read more on DECK →
